Xortx Therapeutics Inc is a biotechnology company dedicated to developing innovative therapies for kidney-related conditions, particularly focused on diseases such as chronic kidney disease and metabolic disorders
The company aims to address significant unmet medical needs by advancing its proprietary drug candidates through clinical trials and bringing novel solutions to patients suffering from these challenging health issues. By leveraging advancements in science and technology, Xortx is committed to improving the quality of life for individuals impacted by kidney diseases.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
New York, NY - March 19, 2024 - In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical pharmaceutical firm specializing in revolutionary treatments for progressive kidney disease, has made headlines with its tremendous progress.
New York, NY, March 19, 2024 – (Plato Data) -- In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical pharmaceutical firm specializing in revolutionary treatments for progressive kidney disease, has made headlines with its tremendous progress.
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's drug candidate following proof-of-concept study data.
U.S. stocks traded lower this morning, with the Dow Jones index falling over 100 points on Monday. Following the market opening Monday, The Dow traded down 0.41% to 32,991.58 while the NASDAQ fell 0.33% to 12,940.56. The S&P 500 also fell, dropping, 0.33% to 4,210.14.
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub.
